Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis

-0.02 (-0.78%)
(As of 02:16 PM ET)
Today's Range
50-Day Range
52-Week Range
1.12 million shs
Average Volume
1.61 million shs
Market Capitalization
$371.43 million
P/E Ratio
Dividend Yield
Price Target

Adaptive Biotechnologies MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
159.5% Upside
$6.80 Price Target
Short Interest
6.57% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.25mentions of Adaptive Biotechnologies in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$428,090 Sold Last Quarter
Proj. Earnings Growth
From ($1.31) to ($1.06) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.74 out of 5 stars

Medical Sector

221st out of 909 stocks

Biological Products, Except Diagnostic Industry

28th out of 156 stocks

ADPT stock logo

About Adaptive Biotechnologies Stock (NASDAQ:ADPT)

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

ADPT Stock Price History

ADPT Stock News Headlines

At first glance, this chart looks like nonsense…
We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”
The system that called 2023’s top 7 stocks is at it again…
Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.
The 7 Best Penny Stocks to Buy in Q2 2024
See More Headlines
Receive ADPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$170.28 million
Book Value
$2.13 per share


Free Float
Market Cap
$374.33 million

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

ADPT Stock Analysis - Frequently Asked Questions

Should I buy or sell Adaptive Biotechnologies stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ADPT shares.
View ADPT analyst ratings
or view top-rated stocks.

What is Adaptive Biotechnologies' stock price target for 2024?

6 Wall Street research analysts have issued 12-month price targets for Adaptive Biotechnologies' shares. Their ADPT share price targets range from $5.00 to $10.00. On average, they predict the company's share price to reach $6.80 in the next year. This suggests a possible upside of 159.5% from the stock's current price.
View analysts price targets for ADPT
or view top-rated stocks among Wall Street analysts.

How have ADPT shares performed in 2024?

Adaptive Biotechnologies' stock was trading at $4.90 at the start of the year. Since then, ADPT shares have decreased by 46.5% and is now trading at $2.62.
View the best growth stocks for 2024 here

Are investors shorting Adaptive Biotechnologies?

Adaptive Biotechnologies saw a increase in short interest in March. As of March 31st, there was short interest totaling 9,100,000 shares, an increase of 7.6% from the March 15th total of 8,460,000 shares. Based on an average trading volume of 1,490,000 shares, the days-to-cover ratio is currently 6.1 days. Approximately 6.6% of the company's stock are sold short.
View Adaptive Biotechnologies' Short Interest

When is Adaptive Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our ADPT earnings forecast

How can I listen to Adaptive Biotechnologies' earnings call?

Adaptive Biotechnologies will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Adaptive Biotechnologies' earnings last quarter?

Adaptive Biotechnologies Co. (NASDAQ:ADPT) released its earnings results on Wednesday, February, 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.02. The firm had revenue of $45.78 million for the quarter, compared to analyst estimates of $50.15 million. Adaptive Biotechnologies had a negative trailing twelve-month return on equity of 53.65% and a negative net margin of 132.29%.

What ETFs hold Adaptive Biotechnologies' stock?

ETFs with the largest weight of Adaptive Biotechnologies (NASDAQ:ADPT) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) and Amplify Treatments, Testing and Advancements ETF (GERM).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

What guidance has Adaptive Biotechnologies issued on next quarter's earnings?

Adaptive Biotechnologies updated its first quarter 2024 earnings guidance on Tuesday, April, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $41.0 million-$43.0 million, compared to the consensus revenue estimate of $38.2 million.

What is Chad Robins' approval rating as Adaptive Biotechnologies' CEO?

51 employees have rated Adaptive Biotechnologies Chief Executive Officer Chad Robins on Chad Robins has an approval rating of 92% among the company's employees. This puts Chad Robins in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adaptive Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptive Biotechnologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Home Depot (HD), Inovio Pharmaceuticals (INO), PayPal (PYPL) and Tesla (TSLA).

When did Adaptive Biotechnologies IPO?

Adaptive Biotechnologies (ADPT) raised $200 million in an IPO on Thursday, June 27th 2019. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers.

Who are Adaptive Biotechnologies' major shareholders?

Adaptive Biotechnologies' stock is owned by a number of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (4.26%) and First Trust Direct Indexing L.P. (0.01%). Insiders that own company stock include Chad M Cohen, Chad M Cohen, Chad M Robins, Chad M Robins, Egon Durban, Euclidean Capital Llc, Francis Lo, Harlan S Robins, Harlan S Robins, Julie Rubinstein, Jyoti Palaniappan, Kyle Piskel, Lance Baldo, Michelle Renee Griffin, Nitin Sood, R Mark Adams, Stacy L Taylor and Tycho Peterson.
View institutional ownership trends

How do I buy shares of Adaptive Biotechnologies?

Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADPT) was last updated on 4/24/2024 by Staff

From Our Partners